Home/Filings/4/0001399529-21-000123
4//SEC Filing

Paglia Regina M. 4

Accession 0001399529-21-000123

CIK 0001399529other

Filed

Jun 21, 8:00 PM ET

Accepted

Jun 22, 4:14 PM ET

Size

13.1 KB

Accession

0001399529-21-000123

Insider Transaction Report

Form 4
Period: 2021-06-17
Paglia Regina M.
Chief Human Resources Officer
Transactions
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-06-174,00057,500 total
    Exercise: $24.05Exp: 2031-01-11Common Stock (4,000 underlying)
  • Exercise/Conversion

    Common Stock

    2021-06-17$12.93/sh+4,664$60,3064,933 total
  • Exercise/Conversion

    Common Stock

    2021-06-17$24.05/sh+4,000$96,2008,933 total
  • Sale

    Common Stock

    2021-06-17$35.79/sh8,664$310,068269 total
  • Exercise/Conversion

    Employee Stock Option (Right to Buy)

    2021-06-174,66498,750 total
    Exercise: $12.93Exp: 2029-02-28Common Stock (4,664 underlying)
Footnotes (4)
  • [F1]The Reporting Person sold an aggregate of 8,664 shares of Common Stock on June 17, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 3.51% of 246,488 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
  • [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.6950 to $35.8750, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  • [F3]The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
  • [F4]The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date.

Issuer

Dicerna Pharmaceuticals Inc

CIK 0001399529

Entity typeother

Related Parties

1
  • filerCIK 0001813985

Filing Metadata

Form type
4
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 4:14 PM ET
Size
13.1 KB